In the treatment of dementia, early and accurate diagnosis is one of the key issues. Often, the early signs of dementia become only apparent when looking back in time. The tendency of physicians to dismiss memory complaints as normal aging should be replaced by an enhanced awareness of mild cognitive impairment.
Mild cognitive impairment (MCI) is the earliest stage of dementia. The difficulty of diagnosis is that this group of patients scores between 27 and 30 on the Mini-Mental State Examination (MMSE), which is a normal score. They may have some difficulties with memory and trouble finding words, but they solve everyday problems and handle their own life affairs well.
However, 70% of those patients diagnosed with MCI progress to develop dementia at some point. Experts recommend that a person diagnosed with MCI to be re-evaluated every six months to determine if symptoms remain the same, improve or worsen.
Cerebrolysin® should be already part of the therapy in the beginning of MCI. The impact of Cerebrolysin® on the transition rate from mild cognitive impairment (MCI) to Alzheimer’s dementia was assessed in studies with a duration of up to three years.
Here the main benefits from Cerebrolysin®:
- Start treatment - The sooner the better
- Remarkable cognitive improvement: +141%
- Better quality of life
- One therapy for all NCDs
Learn more in the new leaflet!